Where the classic diabetes drugs increase insulin, the SGLT2 inhibitors lower it21 by forcing the excretion of glucose outside the body. The result is lower blood glucose, but also lower body weight, blood pressure, and markers of arterial stiffness.22 As the root cause of diabesity is hyperinsulinemia, here, at long last, was a drug that effectively lowered insulin. Would this finally translate into proven cardiovascular benefits? It wasn’t just a home run; it was a grand slam. A 2015 study called the EMPA-REG study (Empagliflozin: Cardiovascular (CV) Outcomes and Mortality in Patients with
...more
